Human
Biologicals Institute (HBI), a division of Indian Immunologicals Ltd (IIL), is
setting up a human vaccine manufacturing facility at Gachibowli near Hyderabad.
An initial investment of around Rs 50 crore is envisaged.
The facility,
which would have a capacity of over 100 million doses per annum, would produce
vaccines such as DPT, hepatitis-B recombinant, measles, and hepatitis-A vaccines.
Civil works are now in progress and commercial production is scheduled to
commence from mid-2003 onwards.
The Institute is
presently engaged in production of only one vaccine – Abhayrab – an anti-rabies
vaccine at its Ooty facility.
IIL, currently
imports vaccines for measles, mumps and rubella (MMR) from the Croatia-based
Institute of Immunology.